Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Identification of two distinct mesenchymal stromal cell populations in human malignant glioma

Svensson, Andreas LU ; Ramos-Moreno, Tania LU orcid ; Eberstål, Sofia LU ; Scheding, Stefan LU and Bengzon, Johan LU (2017) In Journal of Neuro-Oncology 131(2). p.245-254
Abstract

Gene profiling has revealed that malignant gliomas can be divided into four distinct molecular subtypes, where tumors with a mesenchymal gene expression are correlated with short survival. The present investigation was undertaken to clarify whether human malignant gliomas contain endogenous mesenchymal stromal cells (MSC), fulfilling consensus criteria defined by The International Society for Cellular Therapy, recruited from the host. We found that MSC-like cells can be isolated from primary human malignant gliomas. Two distinct MSC-like cell populations, differing in their expression of the CD90 surface marker, were discovered after cell sorting. RNA sequencing revealed further genetic differences between these two cell populations and... (More)

Gene profiling has revealed that malignant gliomas can be divided into four distinct molecular subtypes, where tumors with a mesenchymal gene expression are correlated with short survival. The present investigation was undertaken to clarify whether human malignant gliomas contain endogenous mesenchymal stromal cells (MSC), fulfilling consensus criteria defined by The International Society for Cellular Therapy, recruited from the host. We found that MSC-like cells can be isolated from primary human malignant gliomas. Two distinct MSC-like cell populations, differing in their expression of the CD90 surface marker, were discovered after cell sorting. RNA sequencing revealed further genetic differences between these two cell populations and MSC-like cells lacking CD90 produced higher amounts of VEGF and PGE2 compared to cells with the true MSC phenotype, implying that the CD90− MSC-like cells most probably are more active in tumor vascularization and immunosuppression than their CD90+ counterpart. The results highlight the CD90− subpopulation as an important tumor component, however, its functional effects in glioma remains to be resolved. Using the protocols presented here, it will be possible to isolate, characterize and analyze brain tumor-derived MSC-like cells in more detail and to further test their functions in vitro and in in vivo xenograft models of glioma.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
CD90, Glioblastoma, Malignant glioma, Mesenchymal stromal cell
in
Journal of Neuro-Oncology
volume
131
issue
2
pages
245 - 254
publisher
Springer
external identifiers
  • scopus:84991666935
  • pmid:27757723
  • wos:000394342500005
ISSN
0167-594X
DOI
10.1007/s11060-016-2302-y
language
English
LU publication?
yes
id
ba2e7216-64ca-4999-be3e-7507daf0681a
date added to LUP
2016-11-08 15:09:56
date last changed
2024-05-04 12:35:34
@article{ba2e7216-64ca-4999-be3e-7507daf0681a,
  abstract     = {{<p>Gene profiling has revealed that malignant gliomas can be divided into four distinct molecular subtypes, where tumors with a mesenchymal gene expression are correlated with short survival. The present investigation was undertaken to clarify whether human malignant gliomas contain endogenous mesenchymal stromal cells (MSC), fulfilling consensus criteria defined by The International Society for Cellular Therapy, recruited from the host. We found that MSC-like cells can be isolated from primary human malignant gliomas. Two distinct MSC-like cell populations, differing in their expression of the CD90 surface marker, were discovered after cell sorting. RNA sequencing revealed further genetic differences between these two cell populations and MSC-like cells lacking CD90 produced higher amounts of VEGF and PGE<sub>2</sub> compared to cells with the true MSC phenotype, implying that the CD90<sup>−</sup> MSC-like cells most probably are more active in tumor vascularization and immunosuppression than their CD90<sup>+</sup> counterpart. The results highlight the CD90<sup>−</sup> subpopulation as an important tumor component, however, its functional effects in glioma remains to be resolved. Using the protocols presented here, it will be possible to isolate, characterize and analyze brain tumor-derived MSC-like cells in more detail and to further test their functions in vitro and in in vivo xenograft models of glioma.</p>}},
  author       = {{Svensson, Andreas and Ramos-Moreno, Tania and Eberstål, Sofia and Scheding, Stefan and Bengzon, Johan}},
  issn         = {{0167-594X}},
  keywords     = {{CD90; Glioblastoma; Malignant glioma; Mesenchymal stromal cell}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{245--254}},
  publisher    = {{Springer}},
  series       = {{Journal of Neuro-Oncology}},
  title        = {{Identification of two distinct mesenchymal stromal cell populations in human malignant glioma}},
  url          = {{http://dx.doi.org/10.1007/s11060-016-2302-y}},
  doi          = {{10.1007/s11060-016-2302-y}},
  volume       = {{131}},
  year         = {{2017}},
}